GBS Inc. (GBS) financial statements (2022 and earlier)
Company profile
| Business Address |
733 THIRD AVENUE NEW YORK, NY 10017 |
| State of Incorp. | DE |
| Fiscal Year End | June 30 |
| SIC | 3841 - Surgical and Medical Instruments and Apparatus (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2021 TTM | 6/30/2021 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 11,191 | 12,574 | ||
| Cash and cash equivalents | 11,191 | 12,574 | ||
| Receivables | 1,611 | 2,099 | ||
| Other current assets | 148 | 2,509 | ||
| Other undisclosed current assets | 1,135 | 1,025 | ||
| Total current assets: | 14,085 | 18,207 | ||
| Noncurrent Assets | ||||
| Nontrade receivables | 1,151 | 3,148 | ||
| Other noncurrent assets | 504 | |||
| Total noncurrent assets: | 1,151 | 3,652 | ||
| TOTAL ASSETS: | 15,236 | 21,859 | ||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities, including: | 449 | 1,570 | ||
| Employee-related liabilities | 129 | |||
| Other undisclosed accounts payable and accrued liabilities | 320 | 1,570 | ||
| Deferred revenue | 3,422 | 2,099 | ||
| Due to related parties | 10 | 13 | ||
| Other undisclosed current liabilities | 129 | |||
| Total current liabilities: | 4,009 | 3,683 | ||
| Noncurrent Liabilities | ||||
| Liabilities, other than long-term debt | 1,151 | 3,148 | ||
| Deferred revenue | 1,151 | 3,148 | ||
| Other undisclosed noncurrent liabilities | 31 | 22 | ||
| Total noncurrent liabilities: | 1,182 | 3,170 | ||
| Total liabilities: | 5,191 | 6,853 | ||
| Stockholders' equity | ||||
| Stockholders' equity attributable to parent | 10,105 | 15,058 | ||
| Preferred stock | 13 | |||
| Common stock | 149 | 136 | ||
| Additional paid in capital | 38,440 | 38,440 | ||
| Accumulated other comprehensive loss | (721) | (661) | ||
| Accumulated deficit | (27,762) | (22,870) | ||
| Stockholders' equity attributable to noncontrolling interest | (60) | (51) | ||
| Total stockholders' equity: | 10,045 | 15,007 | ||
| TOTAL LIABILITIES AND EQUITY: | 15,236 | 21,859 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2021 TTM | 6/30/2021 | ||
|---|---|---|---|
| Revenues | 1,820 | 1,980 | |
| Gross profit: | 1,820 | 1,980 | |
| Operating expenses | (10,719) | (7,554) | |
| Operating loss: | (8,899) | (5,573) | |
| Nonoperating income (expense) | 5 | (1,487) | |
| Foreign currency transaction loss, before tax | (265) | ||
| Interest and debt expense | (22) | (1,094) | |
| Loss from continuing operations before equity method investments, income taxes: | (8,916) | (8,154) | |
| Other undisclosed income from continuing operations before income taxes | 22 | 1,094 | |
| Net loss: | (8,895) | (7,060) | |
| Net income attributable to noncontrolling interest | 21 | 23 | |
| Net loss available to common stockholders, diluted: | (8,873) | (7,037) | |
Comprehensive Income ($ in thousands)
| 12/31/2021 TTM | 6/30/2021 | ||
|---|---|---|---|
| Net loss: | (8,895) | (7,060) | |
| Other comprehensive loss | (262) | ||
| Other undisclosed comprehensive loss | (79) | (297) | |
| Comprehensive loss: | (9,235) | (7,358) | |
| Comprehensive income, net of tax, attributable to noncontrolling interest | 21 | 23 | |
| Comprehensive loss, net of tax, attributable to parent: | (9,214) | (7,335) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.